LEADING THE WAY IN ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT

Over the past several decades, Taiho has had a successful track record of producing anti-cancer treatments. These successes have brought us to where we are today, with a strong vision to lead the charge in combining conventional and targeted agents. Our unique two-pronged approach of continuously leveraging expertise in anti-metabolite therapies while also combining them with molecular targeted agents, has uncovered a wide range of promising treatments for the future.

The content listed here is representative of US-based studies. For a full listing of all Taiho studies globally, please see the following:

Taiho Pharmaceutical Company

COMPOUND/MOA COMPOUND/MOA INDICATION DEVELOPMENT STAGE Links

1FUTIBATINIB

FGFR 1-4 inhibitor

Cholangiocarcinoma Second Line Therapy (Pivotal Phase 2)

FILED

1FUTIBATINIB

FGFR 1-4 inhibitor

Breast Cancer with FGFR 1/2 amplification

Phase 2

1FUTIBATINIB

FGFR 1-4 inhibitor

Urothelial Cancer in Combination With Pembrolizumab

Phase 2

1FUTIBATINIB

FGFR 1-4 inhibitor

Non-small cell lung cancer with KRAS mutations in combination with binimetinib

Phase 2

ZIPALERTINIB

Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations

Non-Small Cell Lung Cancer (Phase 1/2)

Phase 2

TAS0612

S6K, AKT, RSK inhibitor

Solid Tumours

Phase 1

TAS2940

ERBB inhibitor

Solid Tumours

Phase 1

All data is current as of November 2022

* This material contains information regarding investigational agents that, unless otherwise indicated have not been approved for commercial use by any country’s Regulatory Authority. In addition, the clinical efficacy and safety for these investigational agents has not been established. There is no guarantee that these compounds will become commercially available or proven safe and effective for any particular therapeutic indication.

1 LYTGOBI® (futibanib) is FDA approved for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.